E. Glazkova

Palbociclib in the first line combination hormone therapy of HER2- negative metastatic hormone-dependent breast cancer. Clinical follow-up

M. Stenina, M. Frolova, E. Glazkova, 2018, Medical Council.

Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function

M. Frolova, S. Menshikova, E. Glazkova, 2018, Medical Council.

Combination of Ixabepilone and Capecitabine in Metastatic Triple Negative Breast Cancer. Clinical case

M. Stenina, E. Glazkova, M. Frolova, 2019 .

Olanzapine (OLN) versus aprepitant (APR) in patients receiving high-emetogenic chemotherapy: Final results of randomized phase II trial.

S. Tjulandin, A. Tryakin, M. Fedyanin, 2019, Journal of Clinical Oncology.